Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Helix Energy Solutions
HLX
$1.54B
| $6.49M | 0.01% |
673,429
+242,202
| +56% | +$2.1M |
|
1702
V2X
VVX
$2.6B
| $6.48M | 0.01% |
126,400
-2,200
| -2% | -$106K |
|
1703
Comscore
SCOR
$93.6M
| $6.47M | 0.01% |
65,532
+10,555
| +19% | +$722K |
|
1704
Diana Shipping
DSX
$309M
| $6.47M | 0.01% |
2,977,432
+363,270
| +14% | +$879K |
|
1705
American Vanguard Corp
AVD
$62.5M
| $6.47M | 0.01% |
332,469
-155,631
| -32% | -$2.45M |
|
1706
Landstar System
LSTR
$6.45B
| $6.47M | 0.01% |
+56,840
| New | +$6.42M |
|
1707
Woodward
WWD
$21.9B
| $6.46M | 0.01% |
54,584
-56,200
| -51% | -$6.34M |
|
|
AVDL
1708
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.45M | 0.01% |
854,006
+32,000
| +4% | +$169K |
|
1709
PVH
PVH
$3.8B
| $6.44M | 0.01% |
61,275
-463,400
| -88% | -$44.2M |
|
|
STFC
1710
DELISTED
State Auto Financial Corp
STFC
| $6.44M | ﹤0.01% |
207,600
-51,168
| -20% | -$1.65M |
|
1711
Liberty Latin America Class A
LILA
$1.69B
| $6.43M | ﹤0.01% |
520,545
+54,698
| +12% | +$636K |
|
1712
Sally Beauty Holdings
SBH
$1.54B
| $6.43M | ﹤0.01% |
+352,300
| New | +$6.12M |
|
1713
Crane NXT
CXT
$2.97B
| $6.43M | ﹤0.01% |
214,198
-29,941
| -12% | -$853K |
|
1714
PIMCO 0-5 Year High Yield Corporate Bond Index Exchange-Traded Fund
HYS
$1.78B
| $6.41M | ﹤0.01% |
64,300
-12,555
| -16% | -$1.24M |
|
1715
Kamada
KMDA
$437M
| $6.41M | ﹤0.01% |
937,829
+107,605
| +13% | +$655K |
|
1716
Natera
NTRA
$44.7B
| $6.4M | ﹤0.01% |
+190,000
| New | +$7M |
|
|
SNCR
1717
DELISTED
Synchronoss Technologies
SNCR
| $6.4M | ﹤0.01% |
149,666
+4,766
| +3% | +$212K |
|
1718
John Wiley & Sons Class A
WLY
$2.61B
| $6.39M | ﹤0.01% |
131,800
-110,300
| -46% | -$5.13M |
|
1719
Mistras Group
MG
$576M
| $6.39M | ﹤0.01% |
447,540
-102,100
| -19% | -$1.44M |
|
1720
Rigel Pharmaceuticals
RIGL
$795M
| $6.37M | ﹤0.01% |
297,694
+108,230
| +57% | +$2.23M |
|
|
FFG
1721
DELISTED
FBL Financial Group
FFG
| $6.35M | ﹤0.01% |
107,700
+13,100
| +14% | +$754K |
|
|
RPT
1722
DELISTED
RPT Realty Common Shares of Beneficial Interest (MD)
RPT
| $6.33M | ﹤0.01% |
421,100
+286,100
| +212% | +$4.09M |
|
1723
SmartFinancial
SMBK
$902M
| $6.32M | ﹤0.01% |
267,377
+72,503
| +37% | +$1.6M |
|
1724
Southern Missouri Bancorp
SMBC
$845M
| $6.32M | ﹤0.01% |
164,634
+3,800
| +2% | +$141K |
|
|
TA
1725
DELISTED
TravelCenters of America LLC
TA
| $6.29M | ﹤0.01% |
366,799
| – | – |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.